Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Authors: Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, G Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Ballo, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger
Institutions: Justus-Liebig-Universität Gießen, Klinikum Leverkusen, Klinikum Ernst von Bergmann, Medizinische Hochschule Hannover, Klinikum Lüdenscheid, St. Bernward Krankenhaus, Krankenhaus Nordwest, Goethe University Frankfurt, University Hospital Frankfurt, WiSP Wissenschaftlicher Service Pharma GmbH (Germany), University of Freiburg, Schwarzwald-Baar Klinikum
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2169209759